The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Erik Penser Bank, Tel: +46 8 463 80 00. Erik Penser Bank equity research

Annual Report

  November 29, 2022

Company Presentation

 October 11, 2022
Download PDF

CEO Comments

Read More
  Annual Report 21/22, November 10 2022
Precision medicine today revolutionizes the treatment of many diseases, not least in cancer. Precision medicine takes into account the fact that we are all unique individuals, which requires an individual therapeutic approach. Treating the right patient with the right drug at the right time focuses resources where they create the most value. We at Diamyd Medical are proud to lead this development in autoimmune diabetes.
We know that by treating patients suffering from autoimmune diabetes with Diamyd®, we have an opportunity to slow down the development of...
We are on the verge of radically changing how autoimmune diabetes should be treated. The antigen-specific immunotherapy Diamyd® targets individuals who carry a specific gene type found in up to 40% of all people who suffer from or are at risk of autoimmune diabetes, a textbook example of precision medicine. This is a great discovery and a paradigm shift in the field.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
January 9 − January 12, 2023
BIO Partnering at JPM
January 9-12, 2023, San Francisco, CA
January 25, 2023
Quarterly Report I
Quarterly Report 1 2022/2023
February 27 − March 1, 2023
6th Antigen-Specific Immune Tolerance Summit
April 5, 2023
Quarterly Report II
Quarterly Report 2 2022/2023
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of September 30, 2022

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 757 473 12.68 9.76
Lindkvist, Bertil 6 240 000 8.11 6.24
Essen-Möller, Anders 556 223 2 813 040 4.38 8.38
Nordnet Pension 3 267 071 4.25 3.27
Essen-Möller, Maria-Teresa 400 000 963 998 1.77 4.97
Essen-Möller, Jon 400 000 612 368 1.32 4.62
Essenshaw, My 400 000 553 774 1.24 4.56
Hillborg, Erika 400 000 490 000 1.16 4.49
Esssen-Möller, Martin 400 000 355 774 0.98 4.36
Konstruktions o Försäljningsaktiebolag 725 000 0.94 0.73
Remaining shareholders 48 592 218 63.17 48.62
Total 2 556 223 74 370 716 100.0 100.0

Order GAD for preclinical research

ORDER

Annual Report

  November 29, 2022
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden

Visiting address:
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research